GlassScriptPhysician profile
Tammy L Seifried
NPI 1285924761
$1,475.80
in general payments reported to CMS, 2019-2025
15 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $508 · 2022: $270 · 2023: $170 · 2024: $298 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $339.20 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbott Laboratories | $231.73 | 2021-2025 | Freestyle Libre |
| Novo Nordisk INC | $231.20 | 2021-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $183.08 | 2021-2022 | |
| Lilly USA, LLC | $182.59 | 2021-2024 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.09 | 2021 | |
| Astellas Pharma US INC | $54.43 | 2025 | Veozah |
| Dexcom, INC. | $40.50 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $39.64 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $30.44 | 2024-2025 | Rexulti |
| Mylan Specialty L.P. | $27.80 | 2023-2024 | Yupelri |
| Xeris Pharmaceuticals, INC. | $16.32 | 2023 | Gvoke Hypopen |
| Viatris Specialty LLC | $14.87 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $14.18 | 2021 | |
| Eisai INC. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Seifried listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.